Sign In
Buy HZNP
$116.30
+0 (+0%)
At Close: Jan 04, 2024
Amgen, Horizon Therapeutics Stocks Jump After FTC Clears Their $28 Billion Marriage
09:28am, Friday, 01'st Sep 2023
Amgen stock jumped Friday after the company confirmed the FTC officially cleared its $28 billion acquisition of Horizon Therapeutics.
FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics
09:20am, Friday, 01'st Sep 2023
The Federal Trade Commission reached a deal with Amgen Inc. AMGN, -0.60% to approve its $27.8 billion acquisition of Horizon Therapeutics plc, HZNP, -0.07% the agency announced Friday.
U.S. FTC allows Amgen to move forward with $27.8 bln Horizon deal - CNBC
09:04am, Friday, 01'st Sep 2023
The U.S. Federal Trade Commission has allowed drugmaker Amgen Inc to move ahead with its $27.8 billion deal to buy Horizon Therapeutics , CNBC reported on Friday.
FTC, Amgen strike deal to allow $27.8 billion Horizon Therapeutics acquisition to move forward
08:49am, Friday, 01'st Sep 2023
The FTC had filed a lawsuit in May seeking to block the acquisition, arguing that the deal would "stifle competition" in the pharmaceutical industry.
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
07:01am, Friday, 01'st Sep 2023
Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen In
Is This the Green Light Biotech Stocks Have Been Waiting For?
07:53am, Thursday, 31'st Aug 2023
Biotech stocks have underperformed the broad market since May, when the Federal Trade Commission moved to block Amgen's proposed acquisition of Horizon Therapeutics. The FTC was aiming to prevent Amge
FTC Attempts To Block Major Biotech Company Merger
11:11pm, Monday, 28'th Aug 2023
The FTC's lawsuit against Amgen-Horizon deal is based on unprecedented speculative concerns and would have cleared months ago if it followed well-established precedent.
Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit
12:47pm, Monday, 28'th Aug 2023
The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises 5.8% in response.
Horizon Therapeutics Shares Surge As FTC Postpones Challenge to Merger
10:50am, Monday, 28'th Aug 2023
Horizon Therapeutics (HZNP) shares jumped more than 5.5% in early trading Monday after the FTC said it would suspend its challenge to Amgen's (AMGN) acquisition of the drug maker.
Horizon Therapeutics shares climb after FTC pauses challenge of deal with Amgen
08:03am, Monday, 28'th Aug 2023
Shares of Horizon Therapeutics PLC HZNP, +0.31% gained more than 5% premarket on Monday after the Federal Trade Commission last week paused its legal challenge to Amgen Inc.'s AMGN, -0.09% deal to acq
US FTC suspends challenge to block Amgen's $27.8 bln deal for Horizon Therapeutics
11:43am, Saturday, 26'th Aug 2023
The U.S. Federal Trade Commission (FTC) has suspended its challenge of Amgen's $27.8 billion purchase of Horizon Therapeutics , allowing the FTC to consider whether the agency should settle the case,
FTC Pauses Challenge to Amgen's $27.8 Billion Deal for Horizon Therapeutics
11:09am, Saturday, 26'th Aug 2023
The move gives the agency time to weigh a settlement that would allow the deal to close with conditions.
Drinks, Chips & Drugs: A Surprising List of 10-Year Stock Winners
01:49pm, Saturday, 12'th Aug 2023
The U.S. stock market has been rattled by a range of events and yet sits within 7% of an all-time high. Along the way, however, many publicly traded companies have gone bankrupt or been delisted.
Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales
01:42pm, Wednesday, 09'th Aug 2023
Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors being Krystexxa and Uplizna.
Compared to Estimates, Horizon Therapeutics (HZNP) Q2 Earnings: A Look at Key Metrics
12:10pm, Tuesday, 08'th Aug 2023
The headline numbers for Horizon Therapeutics (HZNP) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Str
